Maradona Death Trial Rocked by Lab Error as Tests Found to Be His Father’s

An Argentine health insurance company has admitted that key medical tests used in the trial over the death of football legend Diego Maradona did not belong to the 1986 World Cup winner, but to his late father, who shared his name.

Insurer Confirms Misfiled Tests in High-Profile Case

In a letter seen by the court, Swiss Medical acknowledged that laboratory results it provided to a medical commission investigating Maradona’s death “remained mistakenly filed under the name Diego Armando Maradona” when in fact they related to his father, Diego Salustiano Maradona.

The older Maradona died in 2015, five years before the former Argentina captain, who is widely regarded as one of the greatest footballers in history.[[2]] The mix-up means that part of the expert analysis in the current proceedings was based on data from a different patient, with a different medical profile, and from a different period.

The error came to light last week when a lawyer representing one of the seven healthcare professionals on trial flagged inconsistencies in the records and pushed the court to verify the origin of the test results.

Trial Over Maradona’s Final Days

Maradona died in November 2020 at the age of 60 from heart failure and acute pulmonary edema, a condition in which fluid accumulates in the lungs. He passed away at a rented house in the Buenos Aires suburb of Tigre, just two weeks after undergoing surgery for a brain clot.

His final months were marked by complex health issues and a dependence on medical support. The case now before the court is examining whether his care team responded adequately to those challenges in the period between his brain surgery and his death.

Seven medical professionals, including members of his treating team, are accused of providing grossly inadequate care in the lead-up to his death. All deny the charges.

Kidney Evidence Undermined by Wrong Patient Data

The health of Maradona’s kidneys has become a central thread in the latter stages of the trial. A nephrologist, called as an expert witness, argued that his doctors should have paid closer attention to Maradona’s kidney function when managing his overall condition.

It has now emerged that this specialist based part of that assessment on laboratory results that did not belong to the former Napoli and Barcelona playmaker, but to his father. The revelation raises questions about how the evidence was compiled, checked, and incorporated into a case that carries significant legal and reputational stakes for all involved.

For a global football audience, the reliability of such evidence is not a narrow procedural issue. The outcome of this trial will shape how one of the sport’s defining figures is remembered off the pitch, influencing public understanding of whether his death was an unavoidable medical tragedy or the result of preventable failures in care.

Proceedings Paused Amid Fresh Embarrassment

The discovery of the mix-up has led to the suspension of the trial for a week. The interruption adds to an already troubled legal process, after an earlier attempt to try the case collapsed last year due to a conflict of interest involving one of the judges.

The current trial, which began in April, is scheduled to resume on Thursday and is expected to run at least until September, with the court now under pressure to demonstrate that all remaining medical and procedural evidence has been properly verified.

Although the case is being heard in Argentina’s domestic courts, the stakes extend far beyond national boundaries. The handling of Maradona’s death is closely watched by the international football community, where trust in medical protocols and duty-of-care standards is shaped not only by club-level regulations but also by the broader framework set by bodies such as the [[1]].

Legacy Under Legal and Institutional Scrutiny

Maradona’s on-field legacy – most notably leading Argentina to World Cup glory in Mexico in 1986 – has long been established.[[1]] The current proceedings, however, sit at the intersection of sport, law, and healthcare, and carry implications for how elite athletes are protected once the stadium lights are off.

For clubs, national teams, and governing bodies, the case underscores the importance of:

• Robust verification of medical records and test results in high-profile cases.
• Clear delineation of responsibility between insurers, private providers, and treating physicians.
• Transparent procedures when former players with complex medical histories transition from active competition to retirement.

Whatever the court ultimately decides, the revelation that crucial tests were misattributed – and belonged to a different Diego Maradona altogether – adds another layer of complexity to a case that is already reshaping the conversation around medical accountability in elite sport.